Related Videos
Video
Jennifer Brown, MD, PhD discusses results form the ALPINE trial
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Video
Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial
Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.
Video
Jennifer Brown, MD, PhD, Discusses ALPINE Trial
Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23. The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib.
Video
Zanubrutinib improves progression-free survival in relapsed CLL
Dana-Farber's Jennifer Brown, MD, PhD, says the phase 3 ALPINE randomized trial shows the drug zanubrutinib is superior to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and should be considered a new standard of care.
Video
Next Questions: Chronic Lymphocytic Leukemia
Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.